NEW YORK (Reuters Health)—Anti-TNF drugs are more likely to improve growth in children with inflammatory bowel disease (IBD) if they’re given in the earlier stages of puberty, new findings show.¹ Children who achieve remission are also more likely to have satisfactory growth, the research team reported online on Sept. 21 in the Journal of Pediatric…
Articles by Natasha Yetman
Do RA Patients in Clinical Trials for Biologics Represent the Average?
It’s estimated that a majority of patients with rheumatoid arthritis (RA) have been exposed to biologic treatments. However, the randomized controlled trials demonstrating the safety and efficacy of these biologic agents have strict participant eligibility requirements. New research has examined the requirements of 30 trials for biologics and applied those standards to two large clinical cohorts. The result: A majority of these RA patients did not satisfy the criteria…
FDA Approves Ustekinumab for Crohn’s Disease
(Reuters)—Johnson & Johnson says on Monday that the U.S. Food and Drug Administration approved the company’s psoriasis drug, ustekinumab (Stelara), for use in adults with Crohn’s disease. The drug is approved in the U.S. to treat plaque psoriasis and a type of arthritis associated with psoriasis. Crohn’s is a chronic inflammatory condition in the gastrointestinal…
FDA Approves Adalimumab-atto, a Biosimilar of Humira
WASHINGTON (Reuters)—The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie’s top-selling arthritis drug, adalimumab (Humira). The drug, adalimumab-atto (Amjevita), is made by biotechnology company Amgen Inc. and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved…
Novel Astrocytic Autoantibody Associated with Relapsing Meningoencephalomyelitis
NEW YORK (Reuters Health)—An autoantibody to glial fibrillary acidic protein (GFAP) is associated with relapsing autoimmune meningoencephalomyelitis that is responsive to immunotherapy, researchers report. “Autoimmune GFAP meningoencephalomyelitis is the second autoimmune neurological disease in which the target of the immune attack is recognized to be the astrocyte type of brain cell,” Dr. Vanda A. Lennon…
U.S. Justice Department to Push Prosecutors on Opioids
WASHINGTON (Reuters)—The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported on Friday. “You can’t just have an enforcement strategy alone,” Attorney General Loretta Lynch told the newspaper in an interview. She…
Conservative vs. Surgical: What Influences OA Treatment Choices?
Prior research has found that the use of surgery to treat osteoarthritis is increasing, while more conservative treatments, such as physical therapy, are underused. This disparity drove researchers to examine what influences a patient’s treatment choice. They found that a treatment’s characteristics—including a patient’s expectations for effectiveness and risk—affect decision making. Other influences: personal investment and circumstances, as well as support and advice from social networks and healthcare providers…
Psoriasis May Carry Atherosclerosis Risk Similar to that with Diabetes
(Reuters Health)—People with psoriasis may be at increased risk of coronary artery calcium buildup, comparable to that of people with diabetes, according to a new study. Comparing people in their 50s with psoriasis, diabetes or neither disease, researchers found that moderate to severe calcium buildup was about five times as common in people with diabetes…
U.S. FDA Approves Biosimilar to Etanercept
(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Novartis AG’s biosimilar version of Amgen Inc.’s arthritis drug etanercept (Enbrel). The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions, including rheumatoid arthritis and plaque psoriasis, a skin condition. The agency approved the drug as a biosimilar, meaning there is no…
European Group Offers Guidance on Managing Juvenile Dermatomyositis
NEW YORK (Reuters Health)—A European working group has formulated consensus-based recommendations for the diagnosis and treatment of juvenile dermatomyositis (JDM) with the goal of producing a “standard of care” for patients with JDM throughout Europe. The group is part of a European initiative called SHARE [Single Hub and Access point for pediatric Rheumatology in Europe]…
- « Previous Page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- …
- 97
- Next Page »